AFINITOR
-
Opinions on drugs -
Posted on
Dec 22 2009
- Updated on
Jan 29 2010
Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for hospital use.
-
Clinical Benefit
Substantial |
The actual benefit is substantial. |
Clinical Added Value
minor |
AFINITOR offers a minor IAB (grade IV) in treatment strategy in the treatment of advanced renal cancer following failure of VEGF-targeted therapy. |
English version
Contact Us
Évaluation des médicaments